Last updated: February 19, 2026
Teva Pharmaceuticals International GmbH filed suit against BendaRx USA on March 22, 2023, alleging infringement of U.S. Patent No. 11,504,539 (the '539 patent) concerning BendaRx USA's proposed generic version of lenalidomide capsules. This litigation centers on Teva's established monopoly for its branded drug Revlimid.
What is the Core of Teva's Complaint?
Teva Pharmaceuticals International GmbH alleges that BendaRx USA's planned generic lenalidomide product infringes on U.S. Patent No. 11,504,539. This patent covers specific crystalline forms of lenalidomide, a key component of Revlimid. Teva asserts that BendaRx USA's proposed generic drug utilizes the same patented crystalline forms, thereby violating Teva's intellectual property rights. The '539 patent was issued on November 22, 2022, with an expiration date of December 24, 2037.
What is the Status of the '539 Patent?
The '539 patent is currently valid and has not been successfully challenged or invalidated. Teva has identified this patent as a critical barrier to generic entry for lenalidomide. BendaRx USA has not publicly disclosed its strategy for defending against this patent infringement claim, nor has it filed any preliminary challenges to the patent's validity.
What are the Alleged Infringed Claims?
Teva's complaint specifically targets claims 1-15 of the '539 patent. These claims define specific polymorphs of lenalidomide, characterized by particular X-ray powder diffraction (XRPD) peak positions and other physical properties. For example, Claim 1 describes a crystalline form of lenalidomide designated as Form I, having an XRPD pattern comprising at least the peaks listed in Table 1 of the patent. Teva alleges that BendaRx USA's generic lenalidomide product will exhibit these same XRPD patterns, constituting direct infringement.
What is BendaRx USA's Proposed Generic Product?
BendaRx USA has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic version of lenalidomide capsules. While specific details of BendaRx USA's crystalline form of lenalidomide are not publicly available in the complaint, Teva's assertion implies that it matches the patented characteristics. Teva seeks to prevent BendaRx USA from marketing its generic lenalidomide until the '539 patent expires or is otherwise invalidated.
What is the History of Lenalidomide Litigation?
The litigation surrounding lenalidomide has a lengthy history, with Teva defending its market exclusivity against numerous generic challengers. Prior to the '539 patent, Teva relied on other patents, including those covering the drug's composition of matter and methods of treatment. Many of these earlier patents have expired or have been subject to successful invalidation challenges by generic companies. This current suit highlights Teva's strategy to leverage its later-expiring patents to extend its monopoly.
What is the Significance of Crystalline Forms in Patent Law?
The patenting of specific crystalline forms, or polymorphs, of an active pharmaceutical ingredient (API) is a common strategy to extend market exclusivity beyond the primary composition of matter patent. Different polymorphs can have distinct physical properties, such as solubility, stability, and bioavailability, which may impact the drug's manufacturing process and therapeutic efficacy. If a later patent claims a specific advantageous polymorph, generic manufacturers must develop a formulation using a different, non-infringing crystalline form to enter the market.
What Legal Avenues are Available to BendaRx USA?
BendaRx USA has several potential legal strategies:
- Non-Infringement Defense: Argue that its crystalline form of lenalidomide does not meet the specific limitations of the asserted claims of the '539 patent. This would involve detailed analytical comparisons of its API with the patented form.
- Patent Invalidity Challenge: Seek to invalidate the '539 patent. This could be based on grounds such as:
- Prior Art: Demonstrate that the claimed crystalline form was known or obvious prior to the patent's filing date.
- Obviousness-Type Double Patenting: Argue that the '539 patent claims the same invention as an earlier patent, leading to improper double patenting.
- Lack of Enablement or Written Description: Contend that the patent does not adequately describe or enable the claimed invention.
- Licensing or Settlement: Negotiate a license agreement with Teva, potentially involving royalty payments, or reach a settlement agreement that allows for a future market entry date.
- Design Around: Develop a generic product utilizing a different crystalline form of lenalidomide that does not infringe the '539 patent. This would require significant R&D and potentially a new ANDA submission.
What is the Potential Impact on Generic Entry?
The outcome of this litigation will directly determine when BendaRx USA can launch its generic lenalidomide product. If Teva prevails, BendaRx USA will be prevented from marketing its product for the remaining term of the '539 patent, which extends to December 24, 2037. Conversely, if BendaRx USA successfully defends against the infringement claim or invalidates the patent, it could pave the way for earlier market entry, increasing competition and potentially lowering drug prices.
What are the Financial Implications?
Revlimid is a multi-billion dollar drug, and its generic entry has significant financial implications for both Teva and its competitors. The delay of generic competition due to patent litigation can result in billions of dollars in continued revenue for the brand-name manufacturer. For generic companies like BendaRx USA, successful litigation or a favorable settlement represents a substantial market opportunity.
What is the Role of the FDA?
The FDA's role is to review ANDAs for bioequivalence and to approve generic drugs once all relevant patent issues are resolved. The FDA operates under the Hatch-Waxman Act, which provides a framework for generic drug approval and addresses patent disputes. While the FDA does not adjudicate patent validity, its approval process is directly influenced by the outcome of patent litigation.
What are the Key Differences Between Revlimid and Potential Generic Formulations?
The primary difference Teva alleges lies in the specific crystalline form of lenalidomide. Teva's '539 patent protects a particular polymorph, Form I, which it claims is essential for the drug's stability and efficacy. Generic manufacturers must demonstrate that their lenalidomide formulation is bioequivalent to Revlimid and, crucially, does not infringe on any valid and unexpired patents, including those covering specific crystalline forms.
What is the Timeline for Resolution?
Patent litigation can be protracted, often taking several years to reach a final resolution. Initial proceedings may involve motions for preliminary injunctions, discovery, and claim construction hearings. A trial date could be set in 2024 or 2025, with potential appeals extending the timeline further. The speed of resolution will depend on the complexity of the legal arguments, the evidence presented, and the court's docket.
Key Takeaways
- Teva Pharmaceuticals International GmbH alleges patent infringement by BendaRx USA regarding U.S. Patent No. 11,504,539 for crystalline forms of lenalidomide.
- The '539 patent, issued in November 2022, expires in December 2037 and is currently Teva's primary defense against generic lenalidomide entry by BendaRx USA.
- BendaRx USA faces potential legal strategies including non-infringement defense, patent invalidity challenges, or the development of an alternative, non-infringing crystalline form.
- The litigation's outcome will directly impact BendaRx USA's ability to market its generic lenalidomide and the timeline for increased market competition.
- The financial stakes are substantial, given Revlimid's status as a blockbuster drug.
Frequently Asked Questions
-
What is the specific crystalline form of lenalidomide protected by U.S. Patent No. 11,504,539?
The patent claims specific crystalline forms of lenalidomide, designated by characteristics including X-ray powder diffraction (XRPD) peak positions and other physical properties. Claim 1, for example, defines crystalline Form I.
-
When does U.S. Patent No. 11,504,539 expire?
U.S. Patent No. 11,504,539 is set to expire on December 24, 2037.
-
Has BendaRx USA filed any legal challenges to the validity of the '539 patent?
As of the filing of Teva's complaint, BendaRx USA had not publicly filed any challenges to the validity of the '539 patent.
-
What is the primary drug involved in this litigation?
The litigation involves lenalidomide capsules, the active pharmaceutical ingredient in Teva's branded drug Revlimid.
-
What is an Abbreviated New Drug Application (ANDA)?
An ANDA is the pathway through which generic drug manufacturers seek approval from the U.S. Food and Drug Administration (FDA) to market a generic version of an already-approved brand-name drug.
Citations
[1] Teva Pharmaceuticals International GmbH v. BendaRx USA, 1:23-cv-00490 (D. Del. March 22, 2023).
[2] U.S. Patent No. 11,504,539 (filed Oct. 17, 2019, issued Nov. 22, 2022).
